SA
ALNY icon

Seneschal Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Seneschal Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$603 Buy
2
+1
+100% +$302 ﹤0.01% 359
2026
Q1 		$331 Hold
1
– – ﹤0.01% 460
2025
Q4 		$398 Hold
1
– – ﹤0.01% 418
2025
Q3 		$456 Buy
+1
New +$407 ﹤0.01% 382

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Seneschal Advisors's ALNY Position: Q2 2026 in Review

Seneschal Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 100% in Q2 2026, buying an estimated $302 and bringing the position to 2 shares worth $603. The position accounts for ﹤0.01% of the portfolio, ranked #359.

Seneschal Advisors first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Seneschal Advisors held 2 shares of Alnylam Pharmaceuticals worth $603 as of Q2 2026.
  • Seneschal Advisors bought 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $302.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Seneschal Advisors's portfolio in Q2 2026, its #359 holding.
  • Seneschal Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Seneschal Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.